Back to Carlyle Group Inc. Carlyle Group Inc.

SYRESYRE
Showing 6 of 9 quarters

Position history for Carlyle Group Inc.Carlyle Group Inc.'s holdings in SPYRE THERAPEUTICS INC

No. Carlyle Group exited its SYRE (Spyre Therapeutics) position in Q2 2026. Its Q1 2026 13F listed 9,620 shares worth $485,233. Carlyle Group first reported SYRE in Q4 2023 and held it in 7 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$282,443

Total Shares Change

-9,620

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$88.78
0
2026-Q1
Unchanged
9,620
0.0%
$485,2330.0%$50.44
0
2025-Q4
New
9,620
-
$315,0550.0%$32.76
36
2025-Q1
Exited
0
-100.0%
$00.0%$16.14
0
2024-Q4
Unchanged
9,620
0.0%
$223,7610.0%$23.28
0
2024-Q3
Unchanged
9,620
0.0%
$282,4430.0%$29.41
0

Other major holders of SYRE: FMR LLC, BlackRock, Inc., RTW INVESTMENTS, LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used